Kari Luther Rosbeck joined the TS Alliance in June 2001 and became President and CEO in November 2007. She has been involved in nonprofit fundraising and volunteer management for more than 30 years. During Kari's tenure as President & CEO, the TS Alliance established a comprehensive research program fostering collaboration with industry and academia to move treatments for TSC forward in a more expedited way. The Unlock the Cure research strategy focuses on key points along the drug discovery path and has also served as a capital fundraising campaign. Because of her leadership, the organization has taken an active role in educating the TSC community about clinical trials to diminish the time for recruitment, including pivotal trials that have led to three approvals of a drug for SEGA, angiomyolipomas and partial-onset epilepsy associated with TSC and the first CBD FDA approved product for seizures associated with TSC.